Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

Astellas Pharma logo
$11.66
-0.02 (-0.17%)
(As of 11/1/2024 ET)

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Key Stats

Today's Range
$11.39
$12.11
50-Day Range
$11.28
$12.64
52-Week Range
$9.15
$13.14
Volume
51,601 shs
Average Volume
234,402 shs
Market Capitalization
$21.10 billion
P/E Ratio
55.53
Dividend Yield
2.57%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALPMY Stock News Headlines

Astellas Pharma H1 Profit Rises; Lifts FY24 Outlook
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update
Crypto Crash Ahead? (27 Experts Weigh In)
Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!
Astellas Pharma Withdraws EU Application for Key Drug
Bernstein Releases a Buy Rating on Astellas Pharma (ALPMF)
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
Astellas Pharma's Cancer Drug Vyloy Gets FDA Approval
See More Headlines

ALPMY Stock Analysis - Frequently Asked Questions

Astellas Pharma's stock was trading at $11.90 at the beginning of the year. Since then, ALPMY shares have decreased by 2.0% and is now trading at $11.66.
View the best growth stocks for 2024 here
.

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its earnings results on Wednesday, October, 30th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $3.11 billion for the quarter. Astellas Pharma had a net margin of 3.26% and a trailing twelve-month return on equity of 10.33%.

Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others.

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
10/30/2024
Today
11/02/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
Fax
N/A
Employees
14,754
Year Founded
1923

Profitability

Net Income
$113 million
Pretax Margin
1.55%

Debt

Sales & Book Value

Annual Sales
$11.11 billion
Cash Flow
$1.10 per share
Book Value
$5.84 per share

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$21.10 billion
Optionable
Not Optionable
Beta
0.37

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (OTCMKTS:ALPMY) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners